ID: ALA5268658

Max Phase: Preclinical

Molecular Formula: C11H11ClN2O

Molecular Weight: 222.68

Representations

Canonical SMILES:  C[C@@H]1CC(=O)NN=C1c1ccc(Cl)cc1

Standard InChI:  InChI=1S/C11H11ClN2O/c1-7-6-10(15)13-14-11(7)8-2-4-9(12)5-3-8/h2-5,7H,6H2,1H3,(H,13,15)/t7-/m1/s1

Standard InChI Key:  VECYAKYVLADWSP-SSDOTTSWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 222.68

Molecular Weight (Monoisotopic): 222.0560

AlogP: 2.20

#Rotatable Bonds: 1

Polar Surface Area: 41.46

Molecular Species: NEUTRAL

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.79

CX Basic pKa: 0.91

CX LogP: 2.15

CX LogD: 2.15

Aromatic Rings: 1

Heavy Atoms: 15

QED Weighted: 0.78

Np Likeness Score: -0.70

References

1. Lewis TA, de Waal L, Wu X, Youngsaye W, Wengner A, Kopitz C, Lange M, Gradl S, Ellermann M, Lienau P, Schreiber SL, Greulich H, Meyerson M..  (2019)  Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.,  10  (11): [PMID:31749907] [10.1021/acsmedchemlett.9b00360]

Source

Source(1):

• Scientific Literature